Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.10
- Piotroski Score 2.00
- Grade Overweight
- Symbol (MRNA)
- Company Moderna, Inc.
- Price $43.37
- Changes Percentage (1.45%)
- Change $0.62
- Day Low $41.55
- Day High $44.11
- Year High $170.47
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $145.00
- High Stock Price Target $304.00
- Low Stock Price Target $55.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$15.59
- Trailing P/E Ratio -9.69
- Forward P/E Ratio -9.69
- P/E Growth -9.69
- Net Income $-4,714,000,000
Income Statement
Quarterly
Annual
Latest News of MRNA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Moderna Inc (MRNA) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
If the DSMB recommends unblinding due to meeting vaccine efficacy criteria, interim data will be shared. Moderna does not provide guidance on market share but aims for a flu-COVID combination vaccine ...
By Yahoo! Finance | 4 days ago -
Moderna (MRNA) Q3 2024 Earnings Call Transcript
The Moderna earnings call discussed financial results, cost savings, COVID vaccine sales, clinical programs, and pipeline updates. The company aims to drive sales, cost efficiency, and vaccine approva...
By Yahoo! Finance | 5 days ago -
Buy, Sell, Or Hold MRNA Stock?
Moderna's stock price dropped by 48% this year but is expected to rebound after strong Q3 results. The company beat revenue estimates due to high Covid-19 vaccine sales. With a promising RSV vaccine a...
By Forbes | 5 days ago
